<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Neuromuscular Diseases</journal-id><journal-title-group><journal-title xml:lang="en">Neuromuscular Diseases</journal-title><trans-title-group xml:lang="ru"><trans-title>Нервно-мышечные болезни</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2222-8721</issn><issn publication-format="electronic">2413-0443</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">25</article-id><article-id pub-id-type="doi">10.17650/2222-8721-2014-0-3-13-19</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>LECTURES AND REVIEWS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ЛЕКЦИИ И ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Adequate managment of patients with dystrophinopathies (muscular dystrophy Duchenne/Becker): objective scales and additional diagnostic methods</article-title><trans-title-group xml:lang="ru"><trans-title>Адекватный менеджмент пациентов с дистрофинопатиями (мышечная дистрофия Дюшенна/Беккера): применение объективизирующих шкал и дополнительных методов исследования</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Nosko</surname><given-names>A. S.</given-names></name><name xml:lang="ru"><surname>Носко</surname><given-names>А. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>nosko.anastasia@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kurenkov</surname><given-names>A. L.</given-names></name><name xml:lang="ru"><surname>Куренков</surname><given-names>А. Л.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Nikitin</surname><given-names>S. S.</given-names></name><name xml:lang="ru"><surname>Никитин</surname><given-names>С. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Zykov</surname><given-names>V. P.</given-names></name><name xml:lang="ru"><surname>Зыков</surname><given-names>В. П.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">ROS “Specialists on Neuromuscular Disorders Society”, Moscow</institution></aff><aff><institution xml:lang="ru">ГБОУ ДПО РМАПО Минздрава России, Москва</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">SBEI RMAPGS Ministry of Public Health Russia, Moscow</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научный центр здоровья детей», Москва</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">FSBSI “Sientific Centre of Children Health”, Moscow</institution></aff><aff><institution xml:lang="ru">Региональная общественная организация «Общество специалистов по нервно-мышечным болезням», Москва</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2014-09-19" publication-format="electronic"><day>19</day><month>09</month><year>2014</year></pub-date><volume>4</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>13</fpage><lpage>19</lpage><history><date date-type="received" iso-8601-date="2015-02-19"><day>19</day><month>02</month><year>2015</year></date><date date-type="accepted" iso-8601-date="2015-02-19"><day>19</day><month>02</month><year>2015</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2014, Nosko A.S., Kurenkov A.L., Nikitin S.S., Zykov V.P.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2014, Носко А.С., Куренков А.Л., Никитин С.С., Зыков В.П.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="en">Nosko A.S., Kurenkov A.L., Nikitin S.S., Zykov V.P.</copyright-holder><copyright-holder xml:lang="ru">Носко А.С., Куренков А.Л., Никитин С.С., Зыков В.П.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://nmb.abvpress.ru/jour/article/view/25">https://nmb.abvpress.ru/jour/article/view/25</self-uri><abstract xml:lang="en"><p>There are still no guidlines on managment of Duchenne/Becker myodystrophy in domestic medical practice. It leads to decrease of quality of life and, what is more important, lifespan of patients. In this article we have described our Western coleagues lаst decade experience, including consensus guidelines published in 2010 on mаnаgment of Duchenne myodystrophy, supplemented with our practicle experience. We have described standardized motor development scale and muscle tone score for patients with MDD/MDB, and algorithm of multidiscipline care with focus on prevention, diagnosis and treatment of main disease and steroid therapy complications: cardiovascular, orthopedics, respirator etc. These recommendations not only improve quality of live and extend lifespan of MDD/MDB patients, but allow to take part in multicentre trials on searching of pathognomonic and symptomatic treatment.</p></abstract><trans-abstract xml:lang="ru"><p/></trans-abstract><kwd-group xml:lang="en"><kwd>dystrophynopathy</kwd><kwd>Duchenne muscular dystrophy</kwd><kwd>Becker muscular dystrophy</kwd><kwd>neuromuscular disorders</kwd><kwd>Hammersmith scale</kwd><kwd>Hammersmith manuale muscle testing score</kwd><kwd>Duchenne myodystrophy complications</kwd><kwd>Becker myodystrophy complications</kwd><kwd>cardiomyopathy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>дистрофинопатии</kwd><kwd>мышечная дистрофия Дюшенна</kwd><kwd>мышечная дистрофия Беккера</kwd><kwd>нейромышечные заболевания</kwd><kwd>шкала Хаммерсмит</kwd><kwd>шкала мануального тестирования мышц Хаммерсмит</kwd><kwd>осложнения мышечной дистрофии Дюшенна</kwd><kwd>осложнения мышечной дистрофии Беккера</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Emery A.E. The muscular dystrophies. Lancet 2002;359:687.</mixed-citation><mixed-citation xml:lang="ru">Emery A.E. The muscular dystrophies. Lancet 2002;359:687.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Rivier F., Meyer P., Walther-Louvie U. et al. Врожденные мышечные дистрофии: классификация и диагностика. Нервно-мышечные болезни 2014;1;6–20.</mixed-citation><mixed-citation xml:lang="ru">Rivier F., Meyer P., Walther-Louvie U. et al. Врожденные мышечные дистрофии: классификация и диагностика. Нервно-мышечные болезни 2014;1;6–20.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Bushby K., Connor E. Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings. Clin Investig (Lond)2011;1(9):1217–35.</mixed-citation><mixed-citation xml:lang="ru">Bushby K., Connor E. Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings. Clin Investig (Lond)2011;1(9):1217–35.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Mayhew A.G., Cano S.J., Scott E. et al. Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Dev Med Child Neurology 2013;55:1046–52.</mixed-citation><mixed-citation xml:lang="ru">Mayhew A.G., Cano S.J., Scott E. et al. Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Dev Med Child Neurology 2013;55:1046–52.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Montes J., Gordon A.M., Pandya S. et al. Clinical outcome measures in spinal muscular atrophy. J Child Neurol 2009;24(8):968–78.</mixed-citation><mixed-citation xml:lang="ru">Montes J., Gordon A.M., Pandya S. et al. Clinical outcome measures in spinal muscular atrophy. J Child Neurol 2009;24(8):968–78.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Kissel J.T., Scott C.B., Reyna S.P. et al. SMA carni-VAL trial part II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy. PLoS One 2011;6(7):e21296.</mixed-citation><mixed-citation xml:lang="ru">Kissel J.T., Scott C.B., Reyna S.P. et al. SMA carni-VAL trial part II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy. PLoS One 2011;6(7):e21296.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Swoboda K.J., Scott C.B., Crawford T.O. et al. SMA Carni-VAL trial part I: doubleblind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS One 2010;5(8):e 12140.</mixed-citation><mixed-citation xml:lang="ru">Swoboda K.J., Scott C.B., Crawford T.O. et al. SMA Carni-VAL trial part I: doubleblind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS One 2010;5(8):e 12140.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Bushby K., Finkel R., Birnkrant D.J. et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010;9:177.</mixed-citation><mixed-citation xml:lang="ru">Bushby K., Finkel R., Birnkrant D.J. et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010;9:177.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Darras B.T. Treatment of Duchenne and Becker muscular dystrophy. Official Topic from UpToDate®. 2014. 23 p.</mixed-citation><mixed-citation xml:lang="ru">Darras B.T. Treatment of Duchenne and Becker muscular dystrophy. Official Topic from UpToDate®. 2014. 23 p.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Nolan M.A., Jones O.D., Pedersen RL., Johnston H.M. Cardiac assessment in childhood carriers of Duchenne and Becker muscular dystrophies. Neuromuscul Disord 2003;13:129.</mixed-citation><mixed-citation xml:lang="ru">Nolan M.A., Jones O.D., Pedersen RL., Johnston H.M. Cardiac assessment in childhood carriers of Duchenne and Becker muscular dystrophies. Neuromuscul Disord 2003;13:129.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Colan S.D. Evolving therapeutic strategies for dystrophinopathies: potential for conflict between cardiac and skeletal needs. Circulation 2005;112:2756.</mixed-citation><mixed-citation xml:lang="ru">Colan S.D. Evolving therapeutic strategies for dystrophinopathies: potential for conflict between cardiac and skeletal needs. Circulation 2005;112:2756.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Duboc D., Meune C., Lerebours G. et al. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 2005;45:855.</mixed-citation><mixed-citation xml:lang="ru">Duboc D., Meune C., Lerebours G. et al. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 2005;45:855.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Jefferies J.L., Eidem B.W., Belmont J.W. et al. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation 2005;112:2799.</mixed-citation><mixed-citation xml:lang="ru">Jefferies J.L., Eidem B.W., Belmont J.W. et al. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation 2005;112:2799.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Passamano L., Taglia A., Palladino A. Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients. Acta Myologica 2012; XXXI: 121–5.</mixed-citation><mixed-citation xml:lang="ru">Passamano L., Taglia A., Palladino A. Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients. Acta Myologica 2012; XXXI: 121–5.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Finder J.D., Birnkrant D., Carl J.et al. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am J Respir Crit Care Med 2004;170:456.</mixed-citation><mixed-citation xml:lang="ru">Finder J.D., Birnkrant D., Carl J.et al. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am J Respir Crit Care Med 2004;170:456.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. Birnkrant D.J., Bushby K.M., Amin R.S. et al. The respiratory management of patients with duchenne muscular dystrophy: a DMD care considerations working group specialty article. Pediatr Pulmonol 2010;45:739.</mixed-citation><mixed-citation xml:lang="ru">Birnkrant D.J., Bushby K.M., Amin R.S. et al. The respiratory management of patients with duchenne muscular dystrophy: a DMD care considerations working group specialty article. Pediatr Pulmonol 2010;45:739.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17. Do T. Orthopedic management of the muscular dystrophies. Curr Opin Pediatr 2002; 14:50.</mixed-citation><mixed-citation xml:lang="ru">Do T. Orthopedic management of the muscular dystrophies. Curr Opin Pediatr 2002; 14:50.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18. Cheuk D.K., Wong V., Wraige E. et al. Surgery for scoliosis in Duchenne muscular dystrophy. Cochrane Database Syst Rev 2013; 2:CD005375.</mixed-citation><mixed-citation xml:lang="ru">Cheuk D.K., Wong V., Wraige E. et al. Surgery for scoliosis in Duchenne muscular dystrophy. Cochrane Database Syst Rev 2013; 2:CD005375.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19. Bachrach L.K. Taking steps towards reducing osteoporosis in Duchenne muscular dystrophy. Neuromuscul Disord 2005; 15:86.</mixed-citation><mixed-citation xml:lang="ru">Bachrach L.K. Taking steps towards reducing osteoporosis in Duchenne muscular dystrophy. Neuromuscul Disord 2005; 15:86.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20. Biggar W.D., Bachrach L.K., Henderson R.C. et al. Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004. Neuromuscul Disord 2005;15:80.</mixed-citation><mixed-citation xml:lang="ru">Biggar W.D., Bachrach L.K., Henderson R.C. et al. Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004. Neuromuscul Disord 2005;15:80.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">21. Quinlivan R., Roper H., Davie M. et al. Report of a Muscular Dystrophy Campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and prevention. Neuromuscul Disord 2005;15:72.</mixed-citation><mixed-citation xml:lang="ru">Quinlivan R., Roper H., Davie M. et al. Report of a Muscular Dystrophy Campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and prevention. Neuromuscul Disord 2005;15:72.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
